NLBNPIT20888 20351221 85.2902 (P20888) News

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel, June 17, 2024 HOLON, Israel, June 17, 2024 /PRNewswire/...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen Reports First Quarter 2024 Results

Compugen Reports First Quarter 2024 Results PR Newswire HOLON, Israel, May 20, 2024 Enrollment completed and on track to present data from COM701...

U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip

U.S. index futures showed a slight uptick in Monday’s pre-market, buoyed by the Dow Jones closing above...

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential PR Newswire HOLON, Israel, May...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen Appoints David Silberman as Chief Financial Officer

Compugen Appoints David Silberman as Chief Financial Officer PR Newswire HOLON, Israel, May 15, 2024 HOLON...

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 PR Newswire HOLON, ISRAEL, May 6, 2024 HOLON, ISRAEL, May 6, 2024...

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal...

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel, April 10, 2024...

Compugen to Participate in Two Upcoming Investor Conferences

Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel, April 3, 2024 HOLON, Israel, April 3, 2024 /PRNewswire/...

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy PR Newswire HOLON, Israel, March 11, 2024 HOLON...

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 PR Newswire HOLON, Israel, March 6, 2024 HOLON, Israel...